Prenetics Lands Major Funding for IM8 Brand Expansion
Prenetics, a global consumer health company known for its AI-native direct-to-consumer wellness brand IM8, has announced a significant milestone. The company, co-founded by Danny Yeung and Lawrence Tzang, has secured a $1 billion growth financing round led by General Catalyst's Customer Value Fund (CVF). The announcement was made on July 14, 2026, from their location in New York, USA.
Company Overview
Prenetics, listed on NASDAQ as PRE, has made notable strides in the consumer health sector. Its flagship brand, IM8, co-founded with soccer legend David Beckham, has gained substantial traction globally. The brand is NSF Certified and is currently available in 43 countries, making it one of the fastest-growing premium supplement brands.
Funding Details
This substantial $1 billion financing will primarily focus on expanding IM8’s market presence. General Catalyst's CVF will finance up to 70% of IM8’s marketing expenditures, allowing Prenetics to maintain full control over the use of the funds. In return, General Catalyst will receive a capped share of income tied to the performance of customer cohorts financed through the program.
Financial Performance and Projections
IM8 has already achieved impressive milestones, with over 50 million servings delivered to date. The brand currently delivers approximately 200,000 servings daily, with an order placed every 27 seconds. Prenetics has increased its full-year 2026 revenue guidance for IM8 to a range of $210–220 million, up from the previous $190–210 million. They expect the brand to reach an annualized run-rate revenue of $300 million by the end of 2026 and project full-year 2027 revenue to exceed $400 million.
Strategic Use of Funds
The funds will be strategically used to enhance IM8's marketing efforts. This move is expected to further drive customer acquisition and brand growth. Prenetics has reported that every dollar invested in customer acquisition has returned $1.44 in gross profit, indicating a strong return on investment across all mature customer cohorts.
Leadership Comments
Danny Yeung, CEO and Co-Founder of Prenetics, expressed confidence in the brand's growth trajectory. He stated, "Our partnership with General Catalyst enables us to scale our marketing efforts significantly while retaining full control over our brand strategy."
Conclusion
With this new influx of capital, Prenetics is well-positioned to enhance its market presence and achieve its ambitious revenue targets. The company's strategic partnership with General Catalyst is expected to further solidify IM8's standing in the global consumer health market.